This page shows the latest Zostavax news and features for those working in and with pharma, biotech and healthcare.
Prospects for GlaxoSmithKline’s new shingle vaccine Shingrix have been raised after US advisors recommended that it should be used instead of rival Zostavax from Merck &Co. ... Shingrix could be used in patients who have previously received Zostavax.
Becomes first alternative to Merck &Co’s Zostavax. GlaxoSmithKline has picked up its second approval for new shingles vaccine Shingrix, a potential blockbuster that is considered key to the company’s ... The FDA has approved Shingrix for the
It is increasingly common with advancing age. GSK is hoping that increased efficacy means it will be favoured ahead of Zostavax and also drive up vaccination rates against shingles, which remain ... In June, the company reported the results of a trial
The results of the Zoster-048 study met its primary objective of showing that people who had received the currently-approved vaccine - Merck &Co's Zostavax - at least five years previously ... after clinical data demonstrated the drug's greater efficacy
Blockbuster hopeful would compete with Merck &Co’s Zostavax. . GlaxoSmithKline has submitted its shingles vaccine Shingrix for European marketing authorisation, following on the heels of its FDA filing last month. ... By contrast, Zostavax -
In contrast, Zostavax' efficacy is generally between 18% and 70% and is known to decline in older people. ... GSK is hoping that increased efficacy means it will be favoured ahead of Zostavax and also drive up vaccination rates against shingles, which
More from news
Approximately 4 fully matching, plus 6 partially matching documents found.
The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...